---
schema_version: "secwatch.filing_event.v1"
accession: "0001564590-21-038623"
form_type: "8-K"
ticker: "VKTX"
cik: "0001607678"
company_name: "Viking Therapeutics, Inc."
filed_at: "2021-07-28T23:59:59+00:00"
generated_at: "2026-06-30T01:40:15.728451+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.55
calibrated_materiality_score: 0.55
confidence: "high"
source: SEC EDGAR
---

# Viking reports Q2 net loss of $15.4M, cash $228.3M; VK2809 VOYAGE enrollment continues

## Summary
- Q2 net loss $15.4M ($0.20/sh) vs $9.6M ($0.13/sh) in Q2 2020; R&D expenses rose to $12.8M from $7.8M.
- Cash, equivalents and short-term investments $228.3M at June 30, down from $248.4M at Dec 31, 2020.
- Phase 2b VOYAGE study of VK2809 for NASH enrolling; top-line data expected in 2022.
- VK0214 Phase 1 met primary and secondary objectives; Phase 1b proof-of-concept trial in X-ALD patients underway.
- Six-month net loss $29.4M ($0.38/sh) vs $19.3M ($0.27/sh) in H1 2020.

## SEC filing metadata
- accession: 0001564590-21-038623
- form_type: 8-K
- ticker: VKTX
- cik: 0001607678
- company_name: Viking Therapeutics, Inc.
- filed_at: 2021-07-28T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.55
- calibrated_materiality_score: 0.55
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1607678/000156459021038623/0001564590-21-038623-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1607678/000156459021038623/vktx-8k_20210728.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001564590-21-038623
- JSON: https://secwatch.observer/filing/0001564590-21-038623.json
- Plain text: https://secwatch.observer/filing/0001564590-21-038623.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.